The Unbeatable Mind Podcast With Mark Divine

Today, Commander Divine speaks with Dylan Beynon, founder and CEO of Mindbloom, a new telemedicine company for clinician-prescribed psychedelic therapy. Dylan has been named a Top 25 Consumer Health Tech Executive, and is one of the top 100 Most Influential People in Psychedelics. Dylan shares his thoughts on the future of psychedelics, how his upbringing inspired him to found Mindbloom, the benefits of ketamine therapy vs. mainstream therapies, and more. Key Takeaways: Why psychedelic therapy? Mental healthcare is the #1 public health crisis in the United States. Yet when you dig into the clinical research around existing treatment options, they just aren’t good enough. SSRIs only work 40-47% of the time, and over 50% of people have severe side effects. Plus, it takes 6-8 weeks to work, if it works at all. At-home ketamine therapy gets immediate results 80% of the time, with less than 5% of clients having mild side effects like nausea. How does ketamine therapy work? Patients are sent a flavored ketamine tab